US FDA Staff Question Data on Dyax Corp. Drug

WASHINGTON, Feb 2 (Reuters) - U.S. drug reviewers are questioning data supplied by Dyax Corp to back an experimental drug to treat a rare swelling disorder, documents released on Monday said.
MORE ON THIS TOPIC